This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
C

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger Patients With AML - Intensive vs. Non-Intensive Approaches"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Christine McMahon
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Christine McMahon
265 views
June 20, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

06:26
ecancer

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

Feat. M. Al Malki, S. Devine
09:04
ecancer

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Mult…

Feat. X. Leleu
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
19:21
SOHO Brazil 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

Feat. J. Lancet
27:26
SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

Feat. J. Lancet
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
28:02
University of Colorado Division of Hematology

2024 Updates in AML

Feat. C. McMahon
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
48:04
Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

Feat. H. Kantarjian
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
27:28
UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis
23:37
Rush University Medical Center

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Feat. E. Bhaimia
12:15
Moffitt Cancer Center

Using Transplant in Patients With p53 Mutant MDS or AML

Feat. H. Elmariah
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale
11:40
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R A…

Feat. W. Jen